New hope for acromegaly: experimental drug aims to tame hormone levels

NCT ID NCT07037420

Recruiting now Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 31 times

Summary

This study tests whether adding a new drug, ALXN2420, to standard acromegaly treatment can better lower a key hormone (IGF-1) linked to the disease. About 60 adults with acromegaly who are already on a stable monthly injection will receive either ALXN2420 or a placebo for 15 weeks. The main goal is to see if the new drug reduces IGF-1 levels more than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Los Angeles, California, 90048, United States
Research Site
RECRUITING

Los Angeles, California, 90095, United States
Research Site
RECRUITING

Torrance, California, 90502, United States
Research Site
WITHDRAWN

Aurora, Colorado, 80045, United States
Research Site
RECRUITING

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

Ann Arbor, Michigan, 48109, United States
Research Site
RECRUITING

Las Vegas, Nevada, 89148, United States
Research Site
RECRUITING

New York, New York, 10032, United States
Research Site
RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

CABA, C1012AAR, Argentina
Research Site
RECRUITING

Ciudad de Buenos Aires, C1180AAD, Argentina
Research Site
RECRUITING

Ciudad de Buenos Aires, C1199, Argentina
Research Site
RECRUITING

Ciudad de Buenos Aires, C1405DCS, Argentina
Research Site
RECRUITING

Curitiba, 80030-110, Brazil
Research Site
RECRUITING

Ribeirão Preto, 14049-901, Brazil
Research Site
RECRUITING

Rio de Janeiro, 20231-092, Brazil
Research Site
RECRUITING

São Paulo, 01420-000, Brazil
Research Site
NOT_YET_RECRUITING

Beijing, 100730, China
Research Site
NOT_YET_RECRUITING

Guangzhou, 510120, China
Research Site
NOT_YET_RECRUITING

Kunming, 650032, China
Research Site
NOT_YET_RECRUITING

Shanghai, 201107, China
Research Site
RECRUITING

Copenhagen, 2100, Denmark
Research Site
RECRUITING

Odense, 5464, Denmark
Research Site
RECRUITING

Budapest, 1083, Hungary
Research Site
RECRUITING

Budapest, 1134, Hungary
Research Site
RECRUITING

Pécs, 7624, Hungary
Research Site
RECRUITING

Szeged, 6725, Hungary
Research Site
RECRUITING

Cona, 44124, Italy
Research Site
RECRUITING

Genoa, 16132, Italy
Research Site
RECRUITING

Messina, 98125, Italy
Research Site
NOT_YET_RECRUITING

Milan, 20132, Italy
Research Site
NOT_YET_RECRUITING

Naples, 80131, Italy
Research Site
RECRUITING

Pisa, 56126, Italy
Research Site
RECRUITING

Roma, 00168, Italy
Research Site
RECRUITING

Kaunas, LT50009, Lithuania
Research Site
RECRUITING

Vilnius, 09112, Lithuania
Research Site
NOT_YET_RECRUITING

Leiden, 2333 ZA, Netherlands
Research Site
RECRUITING

Rotterdam, 3015 CE, Netherlands
Research Site
WITHDRAWN

Bydgoszcz, 85-605, Poland
Research Site
NOT_YET_RECRUITING

Gliwice, 44-102, Poland
Research Site
NOT_YET_RECRUITING

Krakow, 31-501, Poland
Research Site
RECRUITING

Warsaw, 03-242, Poland
Research Site
RECRUITING

Wroclaw, 50-367, Poland
Research Site
RECRUITING

Bucharest, 011863, Romania
Research Site
NOT_YET_RECRUITING

Cluj-Napoca, 400006, Romania

Conditions

Explore the condition pages connected to this study.

ACROMEGALY